1-11 of 11
Scott D. Collins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5810: The impact of scaffold, linker, homogeneity and payload selection on the efficacy and tolerability of anti-tubulin ADCs

Scott D. Collins, Natalie Keirstead, Marc Damelin, Dorin Toader, Katsu Ishida, Niyanta N. Kumar, Kelly L. Lancaster, Kalli C. Catcott, Annika Yau, Mohan Bala, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5810.
https://doi.org/10.1158/1538-7445.AM2024-5810
Published: 22 March 2024
View article titled, Abstract 5810: The impact of scaffold, linker, homogeneity and payload selection on the efficacy and tolerability of anti-tubulin ADCs
Journal Articles

Abstract 1756: Antitumor effect of XMT1660, a B7H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer

Scott D. Collins, Pamela S. Shaw, Shawn P. Fessler, Jason Wang, Rebecca Mosher
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1756.
https://doi.org/10.1158/1538-7445.AM2022-1756
Published: 15 June 2022
View article titled, Abstract 1756: Antitumor effect of XMT1660, a B7H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer
Journal Articles

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye M. Cetinbas, Kalli C. Catcott, Kelly Lancaster, Keith W. Bentley, Suzanna Clark, Susan Clardy, Scott D. Collins, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Eugene W. Kelleher, Travis Monnell, Marina Protopopova, Caitlin Routhier, Cheri Stevenson, Elena Ter-Ovanesyan, Joshua D. Thomas, Alex Uttard, Jason Wang, Phonphimon Wongthida, Ling Xu, Annika Yau, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3503.
https://doi.org/10.1158/1538-7445.AM2022-3503
Published: 15 June 2022
View article titled, Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab
Journal Articles

Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer

Shawn P. Fessler, Jason Wang, Scott D. Collins, LiuLiang Qin, Kenneth Avocetien, Ling Xu, Ronald Eydelloth, Steven Vonderfecht, Chen-Ni Chin, Steven Bradley, Susan Clardy, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Dokyong Kim, Rebecca Mosher, Elena Ter-Ovanesyen, Kelly Slocum, Alex Uttard, Phonphimon Wongthida, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 907.
https://doi.org/10.1158/1538-7445.AM2021-907
Published: 01 July 2021
View article titled, Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer
Journal Articles

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye M. Cetinbas, Kalli C. Catcott, Kelly Slocum, Kenneth Avocetien, Keith W. Bentley, Stephen Bradley, Susan Clardy, Scott D. Collins, Elizabeth Ditty, Timothy Eitas, Brian D. Jones, Eugene W. Kelleher, Winnie Lee, Travis Monnell, Rebecca Mosher, Marina Protopopova, LiuLiang Qin, Pamela Shaw, Elena Ter-Ovanesyan, Joshua D. Thomas, Phonphimon Wongthida, Ling Xu, Liping Yang, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1738.
https://doi.org/10.1158/1538-7445.AM2021-1738
Published: 01 July 2021
View article titled, Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
Journal Articles

Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma

Shawn Fessler, Anouk Dirksen, Scott D. Collins, Ling Xu, Winnie Lee, Jason Wang, Ron Eydelloth, Elena Ter-Ovanesyen, Jeffrey Zurita, Elizabeth Ditty, Barrett Nehilla, Susan Clardy, Susan Clardy, Tyler Carter, Kenneth Avocetien, Mark Nazzaro, Nam Le, Kalli C. Catcott, Alex Uttard, Bingfan Du, Chen-Ni Chin, Rebecca Mosher, Kelly Slocum, Liuliang Qin, David Lee, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 2894.
https://doi.org/10.1158/1538-7445.AM2020-2894
Published: 15 August 2020
View article titled, Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma
Journal Articles

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Malli Cetinbas, Kalli C. Catcott, Kenneth Avocetien, Keith W. Bentley, Stephen Bradley, Tyler Carter, Chen-Ni Chin, Susan Clardy, Scott D. Collins, Timothy Eitas, Brian D. Jones, Eugene W. Kelleher, Rebecca Mosher, Mark Nazzaro, Marina Protopopova, Pamela Shaw, Kelly Slocum, Elena Ter-Ovanesyan, LiuLiang Qin, Joshua D. Thomas, Ling Xu, Liping Yang, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6706.
https://doi.org/10.1158/1538-7445.AM2020-6706
Published: 15 August 2020
View article titled, Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines
Journal Articles

Abstract 2687: Dolasynthen–a novel, homogeneous Auristatin F hydroxypropyl amide antibody-drug conjugate platform

Dorin Toader, Marc Damelin, Anouk Dirksen, Shawn P. Fesler, Scott D. Collins, Barrett J. Nehilla, Jian Xu, Ling Xu, Kalli C. Cattcott, Alex Uttard, Winnie Lee, Susan Clardy, Cheri A. Stevenson, LiuLiang Qin, Patrick R. Conlon, Mariya V. Kozytska, Chen-Ni Chin, David H. Lee, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2687.
https://doi.org/10.1158/1538-7445.AM2019-2687
Published: 01 July 2019
View article titled, Abstract 2687: Dolasynthen–a novel, homogeneous Auristatin F hydroxypropyl amide antibody-drug conjugate platform
Journal Articles

Abstract 2974: Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer

Scott D. Collins, Parmita Saxena, Xiao Y. Li, Yeonju Shim, Lance Ostrom, Nicholas C. Yoder, Kalli C. Catcott, Molly A. McShea, Xiuxia Sun, Sanela Bilic, William R. Tschantz, Meghan Flaherty, Keith Mansfield, Tiancen Hu, Vladimir Capka, Markus Kurz, Ivana Liric Rajlic, Anne Serdakowski London, Duc Nguyen, Rebecca Mosher, Matthew J. Meyer, Aaron Bourret, Jamal Saeh, Scott Cameron, Emma Lees, Carl U. Bialucha
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2974.
https://doi.org/10.1158/1538-7445.AM2016-2974
Published: 15 July 2016
View article titled, Abstract 2974: Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer
Journal Articles

Abstract 872: In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial

Carl U. Bialucha, Scott D. Collins, Yeonju Shim, Xiamei Zhang, Roberto Velazquez, Colleen Kowal, Caroline Bullock, Hongbo Cai, Stacy M. Rivera, Julie M. Goldovitz, Esther Kurth, Alice T. Loo, Guizhi Yang, John Green, Lance Ostrom, Matthew J. Meyer, Rebecca Mosher, Hui Gao, Juliet Williams, Emma Lees
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 872.
https://doi.org/10.1158/1538-7445.AM2016-872
Published: 15 July 2016
View article titled, Abstract 872: In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial
Journal Articles

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Joan T. Garrett, Cammie R. Sutton, Richard Kurupi, Carl Uli Bialucha, Seth A. Ettenberg, Scott D. Collins, Qing Sheng, Jerry Wallweber, Lisa DeFazio-Eli, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2013) 73 (19): 6013–6023.
https://doi.org/10.1158/0008-5472.CAN-13-1191
Published: 01 October 2013
View article titled, Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Open the PDF for Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers in another window
Includes: Supplementary data